MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (Avenue or the Company), a specialty pharmaceutical company focused on the development and commercialization of...
MIAMI, April 24, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (Avenue or the Company), a specialty pharmaceutical company focused on the development and commercialization of...
MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (Avenue or the Company), a specialty pharmaceutical company focused on the development and commercialization of...
- Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 - - Presented positive BAER-101 preclinical...
- Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 - - Presented positive BAER-101 preclinical...
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
Avenue Therapeutics to Present BAER-101 Preclinical Data
MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (œAvenue or the œCompany), a specialty pharmaceutical company focused on the development and commercialization of...
MIAMI, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (Avenue or the Company), a specialty pharmaceutical company focused on the development and commercialization of...
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million